As activist investor William Ackman, a thorn in Zoetis' side for two years, reported that he'd sold off his stake, the animal health giant reported Q4 numbers showing a shaped-up bottom line—the very thing Ackman been pushing for.
After two years of implementing an across-the-board efficiency plan, fine-tuning its product portfolio and getting manufacturing up to speed on Apoquel, animal health giant Zoetis is seeing the fruits of its labors.
Last year, the Centers for Disease Control and Prevention released a report from a survey of more than 10,000 veterinarians revealing that the profession takes a major toll on mental health. Now animal health giant Zoetis is stepping forward to offer support to working veterinarians.
Wireless sensors that clip to cows’ ears are helping farmers monitor activity levels and feeding patterns of the animals, and by extension improving the monitoring for early signs of disease. Now, several companies are angling to grab a piece of this growing market.
Advanced Animal Diagnostics has developed a diagnostic test to help dairy farmers make better use of antibiotics to control mastitis--and now it has a big-name partner to help introduce the product in Europe.
Shares of animal health companies are outperforming the stock market as a whole, thanks largely to strong performances from companies like diagnostics maker IDEXX Laboratories, veterinary hospital chain VCA and drugmaker Zoetis.
On August 8, Zoetis bought Scandinavian Micro Biodevices, a tiny 35-person company that makes “lab-on-a-chip” diagnostics that veterinarians can use in their offices when examining dogs and cats. The move was part of a larger initiative by Zoetis to boost its stature in the booming market for animal diagnostics.
For the second quarter in a row, Zoetis reported better-than-expected earnings, efficiency gains and expectations for 2016, but analysts pressed the company for details on how it plans to maintain the strong momentum.